Mylan’s Acquisition of Bioniche Pharma

On July 14, 2010, Mylan Inc. announced plans to acquire Bioniche Pharma Holdings Limited, a privately held, global injectable pharmaceutical company, for $550 million in cash. Cravath represented Mylan Inc. in this transaction. The transaction is expected to close within 60 days, subject to regulatory approvals and other customary closing conditions. Mylan Inc. ranks among the leading generic and specialty pharmaceutical companies in the world.

The Cravath team included partner Mark I. Greene and associates Aaron Gruber, Aaron B. Holmes and Richard N. Luft on corporate matters; partner Eric W. Hilfers and associate Edward S. Wei on executive compensation and benefits matters; partner Andrew W. Needham on tax matters; partner Elizabeth L. Grayer and practice area attorney Robin C. Landis on antitrust matters; and practice area attorney Matthew Morreale on environmental matters.